<div id="readability-page-1"><ul><li>3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices </li></ul>Executives from Aclaris Therapeutics NASDAQ: ACRS outlined the company’s clinical-stage pipeline and upcoming catalysts during a presentation at Oppenheimer’s Annual Healthcare Conference, emphasizing programs in inflammatory and immunological diseases spanning monoclonal antibodies, a bispecific antibody, and small-molecule kinase inhibitors.<div>Get Aclaris Therapeutics alerts:</div><h2>Company overview and pipeline cadence</h2> Aclaris described itself as a clinical-stage biotechnology company focused on discovering and developing both large- and small-molecule therapeutics for major unmet needs in inflammation and immunology. Management highlighted the team’s prior drug development experience across companies including MedImmune/AstraZeneca, Centocor/J&amp;J, GSK, and Pfizer, noting experience taking programs “from discovery through to the market.” According to the presenters, Aclaris has three clinical-stage programs currently in or having completed proof-of-concept work through Phase 2, as well as another program expected to reach IND submission later this year. Management repeatedly characterized 2026 as a significant year for the company, while also pointing to multiple data readouts expected in the second half of this year. <h2>Bosakitug: anti-TSLP antibody in atopic dermatitis</h2> The company’s most advanced disclosed program is bosakitug, an anti-TSLP monoclonal antibody being studied in atopic dermatitis (AD). Management said bosakitug has what it believes is “best-in-class potential” based on binding characteristics, specifically citing a ~400-hour retention time on TSLP, compared with “about 20 hours or less” for tezepelumab, with other antibodies described as having even shorter retention times. Aclaris previously completed a Phase 2a proof-of-concept study in AD. In discussing that earlier study, management reported over 90% EASI-75 response and over 80% responders in “IJ01”, while also noting the study was open-label. Those results supported advancement into a larger Phase II AD study, which management said is expected to read out top-line data in the second half of this year. On dosing, management said bosakitug has a natural 23-day half-life and suggested that retention time and Phase 2a observations support the possibility of dosing every two to three months. They noted that in the proof-of-concept study the EASI-75 response after the last dose extended through three months. However, the company is using a two-week dosing schedule in the Phase II trial, describing this as a rigorous test designed to maximize exposure and evaluate TSLP as a standalone target in AD while attempting to minimize placebo response through enrollment measures such as using photographs. When asked about expanding bosakitug beyond AD, management said Aclaris is not pursuing additional indications directly. They referenced a separate company, CTTQ, described as having a previous relationship with Biohaven, that is investigating respiratory indications with bosakitug, including a Phase III trial in severe asthma, a Phase III in chronic rhinosinusitis with nasal polyps, and a Phase II in COPD in China. Aclaris said it has focused on AD and would consider partnering if results are strong. <h2>ATI-052: bispecific targeting TSLP and IL-4R</h2> Aclaris also discussed ATI-052, a bispecific antibody combining the TSLP-binding component used in bosakitug with an anti-IL-4 receptor component. Management highlighted Phase I healthy volunteer results, focusing on pharmacokinetics, pharmacodynamics, and safety. In the healthy volunteer study, the company said it engineered ATI-052 with a YTE mutation to help offset target-mediated drug disposition related to IL-4 receptor binding. Management reported a 26-day half-life for ATI-052 and contrasted that to dupilumab, which they described as having a shorter half-life, as well as to a Sanofi competitor candidate (lunsekimig) described as having an eight- to nine-day half-life. They said the observed half-life could potentially support dosing intervals of eight to 12 weeks, depending on dose. Management also described preclinical and ex vivo data, stating that ATI-052 showed four times greater potency in a PBMC assay compared with a combination of tezepelumab plus dupilumab in inhibiting a TSLP/IL-4–activated TARC response. In pharmacodynamic testing using whole blood from healthy volunteers, management said ATI-052 demonstrated up to six weeks of 100% inhibition of the TSLP response at a 360 mg dose, and for the IL-4–activated response showed “up to about three weeks of 100% inhibition” with near-complete inhibition through six weeks. On safety, management said ATI-052’s safety profile in healthy volunteers was “great,” reporting no safety findings attributed to the molecule, no conjunctivitis, and adverse events described as grade 1. <h2>Phase 1b studies in AD and asthma; small-molecule ITK programs</h2> The company said it has initiated two Phase 1b studies for ATI-052: one in AD (announced in January) and one in asthma (announced earlier this week). For the AD Phase 1b, management said the trial enrolls 12 subjects with a 3:1 randomization (nine active, three placebo) and a baseline EASI score of 21, describing the population as more severe than the bosakitug AD study. Dosing is 480 mg administered weekly for five total doses over 28 days, followed by assessment at day 57. Endpoints include EASI, BSA, and IGA, and the company plans extensive PD work including tape strips, with follow-up extended to day 141. For the asthma Phase 1b, management said the study plans to enroll 16 moderate asthma patients (GINA step 2 to 4) with a 3:1 randomization (12 active, four placebo). Patients will receive a single 480 mg dose at baseline, with the primary endpoint assessed at day 28 and focused on FeNO reduction and FEV1 improvement. The initial population is described as TH2-high with a FeNO cutoff greater than 35, with TH2-low exploration expected in later studies. Management said data from both Phase 1b studies are expected in the second half of this year, potentially before the bosakitug Phase II AD readout. Executives argued ATI-052 could offer advantages versus approved therapies by combining TSLP and IL-4 pathway inhibition, potentially expanding reach to broader asthma populations (including T2-low) and offering a less frequent dosing interval relative to dupilumab, while also opening an AD opportunity. On the small-molecule side, Aclaris discussed ATI-2138, described as a potent ITK/JAK3 dual inhibitor. Management said the company believes ITK and JAK3 expression is limited to the immune system and argued this could support a better safety profile than other JAK inhibitors, citing its chronic toxicology studies and clinical data. For indication selection, the company said it is considering areas with mechanistic fit and “white space,” identifying alopecia as a potential lead indication and referencing preclinical work in a severe alopecia model in collaboration with Angela Christiano at Columbia University. Management said it expects to select a lead indication for ATI-2138 by the end of this quarter. Aclaris also highlighted a next-generation ITK-selective effort aimed at reducing JAK3 cross-reactivity. Management identified ATI-9494 as an ITK/TXK inhibitor and said the compound is currently in IND-enabling toxicology studies, with an IND targeted by the end of this year. The company summarized its approach as seeking “JAK-like activity with a better safety profile.”<h2>About Aclaris Therapeutics NASDAQ: ACRS</h2>Aclaris Therapeutics, Inc NASDAQ: ACRS is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company's pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications. Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.<h2>Further Reading</h2><ul><li>Five stocks we like better than Aclaris Therapeutics</li><li>ALERT: Drop these 5 stocks before the market opens tomorrow!</li><li>MAJOR BUY ALERT: Mar-a-Lago/Trump/Elon</li><li>Gilder: Don’t Buy AI Stocks, Do This Instead</li><li>Read this or regret it forever</li><li>What Expenses Can Be Deducted From Capital Gains Tax This Year?</li></ul>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.<h2>Should You Invest $1,000 in Aclaris Therapeutics Right Now?</h2>Before you consider Aclaris Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aclaris Therapeutics wasn't on the list.While Aclaris Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here </div>

IBBQ

Aclaris Therapeutics presented its clinical-stage pipeline at the Oppenheimer Healthcare Conference, focusing on its programs for inflammatory and immunological diseases. The company highlighted its lead candidate, bosakitug, an anti-TSLP monoclonal antibody for atopic dermatitis, which has shown promising Phase 2 results. Aclaris also discussed ATI-052, a bispecific antibody targeting TSLP and IL-4R, with ongoing Phase 1b studies in atopic dermatitis and asthma. Management anticipates significant data readouts in the latter half of this year and considers 2026 a pivotal year for the company.

Market Beat

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

VG Health

Invesco Biotechnology & Genome ETF

Aclaris Therap

iShares Biotechnology ETF

Health Care Select Sector SPDR

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

Ark Genomic Revolution ETF

Aclaris Therapeutics Highlights AD and Asthma Data Catalysts at Oppenheimer Healthcare Conference